Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.

Trial Details

NCT ID

NCT06640166

Phase

PHASE2

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• encorafenib + cetuximab + FOLFIRI

Locations (sample)

• Milan, Italy|42.78235,12.59836
• Roma, Italy|44.99364,11.10642
• Tricase, Italy|39.93018,18.35421

Key Eligibility Criteria

• written informed consent to study procedures;
• age ≥ 18 years;
• histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma;
• radiological evidence of metastatic disease;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.